Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples